Annals of Surgical Oncology

, Volume 23, Issue 3, pp 826–832 | Cite as

A Novel Immune Marker Model Predicts Oncological Outcomes of Patients with Colorectal Cancer

  • Yufeng Chen
  • Ruixue Yuan
  • Xianrui Wu
  • Xiaosheng He
  • Yang Zeng
  • Xinjuan Fan
  • Lei Wang
  • Jianping Wang
  • Ping Lan
  • Xiaojian Wu
Colorectal Cancer

Abstract

Background

The purpose of this study was to develop an in situ immune marker model to predict postoperative oncological outcomes in patients with colorectal cancer (CRC).

Methods

Immunohistochemistry for 13 immune cell markers was performed on tumor tissue microarrays from 300 CRC patients who underwent curative resection from January 2000 to January 2006. Genetic algorithm was applied for the construction of an in situ immune marker model.

Results

The infiltration of CD3+ cells, CD45RO+ cells, and FOXP3+ cells, but not the infiltration of Tryptase+ cells, in the tumor was significantly associated with better clinical outcome in overall survival (OS) and disease-free survival (DFS) of CRC patients, as assessed by univariate analysis (P < 0.05). Based on the genetic algorithms, a total of 6 markers, including CD3, CD45RO, IL17, CD15, Tryptase, and FOXP3, were selected to construct an immune marker model. Our model was identified to have an independent predictive capability for both OS and DFS in Cox multivariable model (P < 0.001). This was further confirmed by the ROC analysis (area under curve: OS, 0.669; DFS, 0.684).

Conclusions

The in situ immune marker model constructed in this study provides a novel approach to identify CRC patients who were at an increased risk for poor oncological outcomes.

Keywords

Overall Survival Lymph Node Ratio Tryptase Immune Cell Infiltration Immune Marker 

Notes

Acknowledgments

We thank Dr. Xueqin Wang (Sun Yat-sen University) and Dr. Patrick Tan (Genome Institute of Singapore) for valuable insights in data analysis. This work was supported by National Key Clinical Discipline, National High Technology Research and Development Program (863) of China (No. 2012AA02A520), International S&T Cooperation Program of China (ISTCP) (No. 2013DFG32990), National Natural Science Foundation of China (NSFC) (No. 81400603), Science and Technology Program of Guangzhou, China (No. 2013J4100113), and Guangdong Department of Science & Technology Translational Medicine Center Grant (No. 2011A080300002).

Disclosure

All the authors declared that there’s no conflict of interest.

Supplementary material

10434_2015_4889_MOESM1_ESM.docx (20 kb)
Supplementary material 1 (DOCX 19 kb)
10434_2015_4889_MOESM2_ESM.docx (18 kb)
Supplementary material 2 (DOCX 18 kb)
10434_2015_4889_MOESM3_ESM.tif (5.9 mb)
Supplementary material 3 (TIFF 6005 kb)
10434_2015_4889_MOESM4_ESM.tif (4 mb)
Supplementary material 4 (TIFF 4106 kb)
10434_2015_4889_MOESM5_ESM.tif (10.4 mb)
Supplementary material 5 (TIFF 10679 kb)
10434_2015_4889_MOESM6_ESM.tif (8.6 mb)
Supplementary material 6 (TIFF 8757 kb)

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004; 96:1420–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Nitsche U, Maak M, Schuster T, et al. Prediction of prognosis is not improved by the seventh and latest edition of the TNM classification for colorectal cancer in a single-center collective. Ann Surg. 2011;254:793–800; discussion 800–1.CrossRefPubMedGoogle Scholar
  4. 4.
    Zlobec I, Karamitopoulou E, Terracciano L, et al. TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer. PLoS One. 2010;5:e14282.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.CrossRefPubMedGoogle Scholar
  6. 6.
    Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.CrossRefPubMedGoogle Scholar
  7. 7.
    Garcia-Martinez E, Gil GL, Benito AC, et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014;16:488.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Schalper KA, Brown J, Carvajal-Hausdorf D, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. 2015;107:dju435.Google Scholar
  9. 9.
    Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306.CrossRefPubMedGoogle Scholar
  10. 10.
    Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol. 2011;33:335–40.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Galon J, Pages F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10:1.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Wu XR, He XS, Chen YF, et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol. 2012;106:130–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Faith DA, Isaacs WB, Morgan JD, et al. Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate. 2004;61:215–27.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Ooi CH, Tan P. Genetic algorithms applied to multi-class prediction for the analysis of gene expression data. Bioinformatics. 2003;19:37–44.CrossRefPubMedGoogle Scholar
  16. 16.
    Rothberg BEG, Berger AJ, Molinaro AM, et al. Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol. 2009;27:5772–80.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Tejpar S, Bertagnolli M, Bosman F, et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist. 2010;15:390–404.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010;375:1030–47.CrossRefPubMedGoogle Scholar
  19. 19.
    Mlecnik B, Bindea G, Angell HK, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med. 2014;6:228ra237.Google Scholar
  20. 20.
    Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782–95.CrossRefPubMedGoogle Scholar
  21. 21.
    Mlecnik B, Bindea G, Pages F, Galon J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev. 2011;30:5–12.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007;67:1883–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222:350–66.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Frey DM, Droeser RA, Viehl CT, et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer. 2010;126:2635–43.PubMedGoogle Scholar
  26. 26.
    Malfettone A, Silvestris N, Saponaro C, et al. High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. J Cell Mol Med. 2013;17:1025–37.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29:610–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Hendriks Y, Franken P, Dierssen JW, et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol. 2003;162:469–77.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Xu J, Ding T, He Q, et al. An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. J Hepatol. 2012;57:313–21.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Yufeng Chen
    • 1
    • 2
  • Ruixue Yuan
    • 2
    • 3
  • Xianrui Wu
    • 1
    • 2
  • Xiaosheng He
    • 1
  • Yang Zeng
    • 1
  • Xinjuan Fan
    • 4
  • Lei Wang
    • 1
    • 2
    • 3
  • Jianping Wang
    • 1
    • 2
    • 3
  • Ping Lan
    • 1
    • 2
    • 3
  • Xiaojian Wu
    • 1
    • 2
    • 3
  1. 1.Department of Colorectal SurgeryThe Sixth Affiliated Hospital, Sun Yat-sen UniversityGuangzhouChina
  2. 2.Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor DiseasesThe Sixth Affiliated Hospital, Sun Yat-sen UniversityGuangzhouChina
  3. 3.Guangdong Institute of GastroenterologyGuangzhouChina
  4. 4.Department of Pathology, The Sixth Affiliated HospitalSun Yat-sen UniversityGuangzhouChina

Personalised recommendations